Delayed
Japan Exchange
01:44:53 2024-05-13 EDT
5-day change
1st Jan Change
1,600
JPY
-0.87%
-1.42%
+2.50%
MOLCURE, Inc. announced that it has received funding from GMO Venture Partners, Inc., Nippon Chemiphar Co., Ltd.
MOLCURE, Inc. announced that it has received series B round of funding in March 2018. The transaction included participation from returning investors GMO Venture Partners, Inc. and Nippon Chemiphar Co., Ltd.
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd.
11-09
CI
Global EV battery supply chain puzzles over China graphite curbs
23-10-27
RE
Delta-Fly Pharma, Inc. announced that it expects to receive ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd.
23-10-19
CI
InnoJin Co., Ltd announced that it has received ¥220 million in funding from Sumitomo Corporation, Nippon Chemiphar Co., Ltd., SEED Co.,Ltd., JINS HOLDINGS Inc.
23-07-03
CI
Nippon Chemiphar Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-12
CI
Activist fund targets maker of Maruchan ramen noodles over governance, sources say
22-05-16
RE
Japan's Hitachi to sell about 50% of its stake in construction unit
22-01-14
RE
MOLCURE, Inc. announced that it has received ¥800 million in funding from JAFCO Group Co., Ltd., STRIVE, Inc., SBI Investment Co., Ltd., Japan Post Capital Co., Ltd., GMO Venture Partners, Inc., Nippon Chemiphar Co., Ltd.
21-08-16
CI
MOLCURE, Inc. announced that it has received ¥100 million in funding from The Dai-Ichi Life Insurance Company, Limited, Nippon Chemiphar Co., Ltd.
18-11-26
CI
MOLCURE, Inc. announced that it has received funding from GMO Venture Partners, Inc., Nippon Chemiphar Co., Ltd.
18-03-30
CI
Tranche Update on Nippon Chemiphar Co., Ltd.'s Equity Buyback Plan announced on January 31, 2018.
18-01-31
CI
Nippon Chemiphar Co., Ltd.'s Equity Buyback announced on January 31, 2018 has expired with 25,000 shares for ¥117.75 million.
18-01-31
CI
Nippon Chemiphar Co., Ltd. announces an Equity Buyback for 30,000 shares, representing 0.82% for ¥141.3 million.
18-01-31
CI
Nippon Chemiphar Co., Ltd. authorizes a Buyback Plan.
18-01-30
CI
Nippon Chemiphar Co., Ltd. Announces the Phase-I Clinical Trial of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor
17-11-29
CI
Nippon Chemiphar Co., Ltd.(TSE:4539) dropped from S&P Global BMI Index
17-09-18
CI
Tranche Update on Nippon Chemiphar Co., Ltd.'s Equity Buyback Plan announced on August 1, 2017.
17-08-01
CI
Nippon Chemiphar Co., Ltd.'s Equity Buyback announced on August 1, 2017 has expired with 192,600 shares, representing 5.05% for ¥999.59 million.
17-08-01
CI
Nippon Chemiphar Co., Ltd. announces an Equity Buyback for 200,000 shares, representing 5.19% for ¥1,038 million.
17-08-01
CI
Nippon Chemiphar Co., Ltd. authorizes a Buyback Plan.
17-07-31
CI
Nippon Chemiphar Co., Ltd. Announces Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Second Quarter and Full Year 2017
17-07-30
CI
Tranche Update on Nippon Chemiphar Co., Ltd.'s Equity Buyback Plan announced on October 31, 2016.
17-04-04
CI
Nippon Chemiphar Co., Ltd's Equity Buyback announced on October 31, 2016 has expired with the repurchase of 94,800 shares for ¥486.76 million.
17-03-30
CI
Nippon Chemiphar Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2016; Revises Earnings Guidance for the Full Year Ending March 31, 2017
17-01-30
CI
Tranche Update on Nippon Chemiphar Co., Ltd.'s Equity Buyback Plan announced on October 31, 2016.
17-01-05
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
NIPPON CHEMIPHAR CO., LTD. is a Japan-based company centered on ethical pharmaceutical products and mainly engaged in the pharmaceutical, health and beauty related businesses. The Companyâs Pharmaceutical segment is engaged in the manufacture and sale of ethical pharmaceutical products. Other businesses include entrusted safety testing, healthcare and real estate leasing business. The Company mainly operates in Japan and Vietnam.
More about the company
1st Jan change
Capi.
+2.50% 37.81M +30.38% 684B +26.51% 568B -4.36% 361B +19.30% 329B +3.73% 284B +16.70% 240B +8.78% 208B -7.93% 200B +7.68% 166B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1